Kaplitt M G, Xiao X, Samulski R J, Li J, Ojamaa K, Klein I L, Makimura H, Kaplitt M J, Strumpf R K, Diethrich E B
Department of Surgery, New York Hospital-Cornell University Medical College, New York, USA.
Ann Thorac Surg. 1996 Dec;62(6):1669-76. doi: 10.1016/s0003-4975(96)00946-0.
Viral vector-mediated gene transfer into the heart represents a potentially powerful tool for studying both cardiac physiology as well as gene therapy of cardiac disease. We report here the use of a defective viral vector, which expresses no viral gene products, for gene transfer into the mammalian heart. Previous studies have used recombinant viral vectors, which retained viral genes and yielded mostly short-term expression, often with significant inflammation.
An adeno-associated virus vector was used that contains no viral genes and is completely free of contaminating helper viruses. The adeno-associated virus vector was applied to rat hearts by direct intramuscular injection; adeno-associated virus was also infused into pig hearts in vivo via percutaneous intraarterial infusion into the coronary vasculature using routine catheterization techniques.
Gene transfer into rat heart yielded no apparent inflammation, and expression was observed for at least 2 months after injection. Infusion into pig circumflex coronary arteries resulted in successful transfer and expression of the reporter gene in cardiac myocytes without apparent toxicity or inflammation; gene expression was observed for at least 6 months after infusion.
We report the use of adeno-associated virus vectors in the cardiovascular system as well as successful myocardial gene transfer after percutaneous coronary artery infusion of viral vectors in a large, clinically relevant mammalian model. These results suggest that safe and stable gene transfer can be achieved in the heart using standard outpatient cardiac catheterization techniques.
病毒载体介导的基因转移至心脏是研究心脏生理学以及心脏病基因治疗的一种潜在有力工具。我们在此报告使用一种缺陷型病毒载体,其不表达病毒基因产物,用于将基因转移至哺乳动物心脏。先前的研究使用的是重组病毒载体,其保留病毒基因且大多产生短期表达,常伴有明显炎症。
使用一种不含病毒基因且完全无辅助病毒污染的腺相关病毒载体。通过直接肌肉注射将腺相关病毒载体应用于大鼠心脏;还使用常规导管插入技术经皮动脉内输注至猪心脏的冠状动脉系统,将腺相关病毒注入猪心脏。
基因转移至大鼠心脏未产生明显炎症,注射后至少2个月观察到表达。注入猪冠状动脉旋支导致报告基因在心肌细胞中成功转移和表达且无明显毒性或炎症;注入后至少6个月观察到基因表达。
我们报告了腺相关病毒载体在心血管系统中的应用,以及在一个大型、临床相关的哺乳动物模型中经皮冠状动脉输注病毒载体后成功的心肌基因转移。这些结果表明,使用标准的门诊心脏导管插入技术可在心脏实现安全稳定的基因转移。